• Search
  • Advanced Search
Clin Mol Hepatol > Accepted Articles
Editorial
Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
Naoshi Nishida
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, 589-8511, Japan
Correspondence :  Naoshi Nishida ,
Tel: +81-72-366-0221 (Ext. 3525), Fax: +81-72-367-2880, Email: naoshi@med.kindai.ac.jp
Received: May 2, 2024   Accepted: May 3, 2024
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 276 View
  • 36 Download
ORCID iDs

Naoshi Nishida
https://orcid.org/0000-0002-9111-5668

Related articles

Correspondence on editorial regarding “Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?”

Surveillance for hepatocellular carcinoma: It is time to move forward2022 October;28(4)

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?2022 July;28(3)

Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?2021 October;27(4)

Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?2017 September;23(3)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 619
TOTAL : 1879712
Close layer